

Theratechnologies Annouces Commercialization Agreement for Egrifta (Tesamorelin for injection) in Europe

February 27, 2015

Theratechnologies Inc. (TSX: TH) is pleased to announce that it has concluded an agreement with AOP Orphan Pharmaceuticals AG (AOP) for the distribution and commercialization of EGRIFTATM in several European countries.